Quince Therapeutics, Inc. (QNCX)
(Delayed Data from NSDQ)
$0.69 USD
0.00 (-0.33%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.71 +0.02 (2.75%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
QNCX 0.69 0.00(-0.33%)
Will QNCX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for QNCX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QNCX
The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
QNCX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for QNCX
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
Quince Therapeutics announces Phase 3 ATTeST trial for A-T evaluated in Lancet